CW Advisors LLC Has $22.76 Million Holdings in Stryker Corporation $SYK

CW Advisors LLC grew its position in shares of Stryker Corporation (NYSE:SYK) by 18.5% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 61,118 shares of the medical technology company’s stock after buying an additional 9,529 shares during the quarter. CW Advisors LLC’s holdings in Stryker were worth $22,759,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also made changes to their positions in SYK. Brighton Jones LLC lifted its holdings in shares of Stryker by 15.4% during the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after buying an additional 609 shares during the last quarter. MML Investors Services LLC raised its stake in shares of Stryker by 8.8% in the 4th quarter. MML Investors Services LLC now owns 38,491 shares of the medical technology company’s stock valued at $13,859,000 after acquiring an additional 3,099 shares in the last quarter. J. Safra Sarasin Holding AG raised its stake in shares of Stryker by 66.6% in the 4th quarter. J. Safra Sarasin Holding AG now owns 2,497 shares of the medical technology company’s stock valued at $899,000 after acquiring an additional 998 shares in the last quarter. Dark Forest Capital Management LP raised its stake in shares of Stryker by 3.3% in the 4th quarter. Dark Forest Capital Management LP now owns 2,483 shares of the medical technology company’s stock valued at $894,000 after acquiring an additional 79 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its stake in shares of Stryker by 0.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 11,109,722 shares of the medical technology company’s stock valued at $4,000,056,000 after acquiring an additional 54,693 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Price Performance

Shares of NYSE:SYK opened at $392.0050 on Thursday. Stryker Corporation has a 1-year low of $329.16 and a 1-year high of $406.19. The firm has a market capitalization of $149.87 billion, a PE ratio of 51.92, a PEG ratio of 2.83 and a beta of 0.91. The business’s 50 day moving average is $387.09 and its 200-day moving average is $379.54. The company has a current ratio of 1.78, a quick ratio of 1.06 and a debt-to-equity ratio of 0.70.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, topping the consensus estimate of $3.07 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The company had revenue of $6.02 billion for the quarter, compared to analyst estimates of $5.92 billion. During the same quarter last year, the firm earned $2.81 EPS. Stryker’s revenue for the quarter was up 11.1% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Sell-side analysts predict that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be paid a $0.84 dividend. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $3.36 annualized dividend and a yield of 0.9%. Stryker’s payout ratio is currently 44.50%.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. JMP Securities reissued a “market perform” rating on shares of Stryker in a research note on Monday, May 5th. Citigroup reissued a “buy” rating and issued a $455.00 price objective (up from $443.00) on shares of Stryker in a research note on Thursday, May 22nd. Roth Mkm raised their price objective on Stryker from $405.00 to $456.00 and gave the company a “buy” rating in a research note on Friday, May 2nd. Evercore ISI lifted their price target on Stryker from $390.00 to $415.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 8th. Finally, Wells Fargo & Company lifted their price target on Stryker from $435.00 to $445.00 and gave the stock an “overweight” rating in a research report on Friday, August 1st. Fifteen investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $430.10.

Insider Buying and Selling

In related news, Director Ronda E. Stryker sold 200,000 shares of the business’s stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total value of $75,290,000.00. Following the sale, the director owned 3,222,108 shares of the company’s stock, valued at $1,212,962,556.60. The trade was a 5.84% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 5.90% of the stock is currently owned by corporate insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.